Clinical Trial

Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 11, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-06-12; most recent amendment 2026-05-06.
Status change: Recruiting → Active, Not Recruiting 2025-09-24
Status change: Not Yet Recruiting → Recruiting 2025-03-17
Trial Details
NCT Number NCT06462222
Lead Sponsor Guangzhou Medical University
Conditions Leptomeningeal Metastasis
Enrollment 45 participants
Start Date 2024-06-30
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-11